Development of somatostatin receptor subtype selective agonists through combinatorial chemistry

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 4, 1999, Pages 293-303

  Rohrer, Susan P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Combinatorial chemistry; Compound library; Mixture screening; Somatostatin receptor

Indexed keywords

BIM 23268; DC 23 99; DC 25100; DC 3297; GLUCAGON; GROWTH HORMONE; INSULIN; L 363377; NC 8 12; OCTREOTIDE; RECEPTOR SUBTYPE; SEGLITIDE; SK 28; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR SELECTIVE AGONIST; SS 28; UNCLASSIFIED DRUG;

ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCAGON RELEASE; GROWTH HORMONE RELEASE; INSULIN RELEASE; MOLECULAR MODEL; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; RECEPTOR SENSITIVITY;

EID: 0032804805     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Lamberts SW, Krenning EP, Reubi JC.The role of somatostatin and its analogs in the diagnosis and treatment of tumors. £ndocrf?ev(1991) 12:450-482.
2. Epelbaum JC.Somatostatin in the central nervous system.physiology and pathological modifications. Prog Neuroblol (1986)27:63-100.
3. Yamada Y, Post SR, Wang K, Tager HS, Bell Gl, Seino S.Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. P roc Natl Acad Sei USA (1992) 89:251 -255.
4. Kluxen F-W, Bruns C, Lübbert H.Expression cloning of a rat brain somatostatin receptor cDNA. Proc Natl Acad Sei USA (1992)89:4618-4622.
5. Vanetti M, Kouba M, Wang X, Vogt G, Höllt V.Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett (1992) 311:290-294.
6. Yasuda K, Rens-Domiano S, Breder CD, Law SF. Saper CB, Reisine T, Bell Gl.Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase. J Biol Chem (1992)267:20422-20428.
7. Meyerhof W, Wulfsen I, Schonrock C, Fehr S, Richter D.Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain. Proc Natl Acad Sei USA (1992) 89:10267-10271.
8. Bruno JF, Xu Y, Song J, Berelowitz M.Molecular cloning and functional expression of a brain-specific somatostatin receptor. Proc Natl Acad Sei USA (1992) 89:11151-11155.
9. Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R.Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sei USA (1993) 90:4196-4200.
10. O'Carroll AM, Lolait SJ, König M, Mahan LC.Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28. Mol Pharmacol (1992) 42:939-946.
11. Law SF, Woulfe D, Reisine T.Somatostatin receptor activation of cellular effector systems. Cell Signal(\995) 7:1-8.
12. Viollet C, Prévost G, Maubert E, Faivre-Bauman A, Gardette R, Kordon C, Loudes C, Slama A, Epelbaum J.Molecular pharmacology of somatostatin receptors. Fundam Clin Pharmacol(1995) 9:107-113.
13. Hunyady B, Hipkin RW, Schonbrunn A, Mezey E.Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. Endocrinology (1997) 138:2632-2635.
14. Mitra SW, Mezey E, Hunyady B, Chameriin L, Hayes E, Poor F, Schonbrunn A, Schaeffer JM.Colocalization of somatostatin receptor sst5 and insulin in the rat pancreatic -cells. Endocrinology (1999) in press.
15. Mezey E, Hunyady B, Mitra S, Hayes E, Liu Q, Schaeffer J, Schonbrunn A.Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology (1998) 139:414-419.
16. Helboe L, Moller M, Norregaard L, Schiodt M, Stidsen CE.Development of selective antibodies against the human somatostatin receptor subtypes sst1-sst5. Mol Brain Res (1997)49:82-88.
17. Zheng H, Bailey A, Jiang MH, Honda K, Chen HY, Trumbauer ME, Van der Pioeg LH, Schaeffer JM, Leng G, Smith RG.Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol Endocrine/(1997) 11:1709-1717.
18. Freidinger RM, Veber DF.Design of novel cyclic hexapeptide somatostatin analogs from a model of the bioactive conformation. In.Conformationally Directed Drug Design. Vida JA, Gordon M (Eds), American Chemical Society (1994).
19. • Discussion of the pharmacophore region of the peptidal somatostatin analogs.
20. Veber DF, Saperstein R, Nutt RF, Freidinger RM, Brady SF, Curley P, Pertow DS, Paleveda WJ, Colton CD, Zacchei AG, Tocco DJ, Hoff DR, Vandlen RL, Gerich JE, Hall L, Mandarine L, Cordes EH, Anderson PS, Hirschmann R.A super active cyclic hexapeptide analog of somatostatin. Life Sei (1984) 34:1371-1378.
21. Coy DH, Taylor JE.Receptor-specific somatostatin analogs.Correlations with biological activity. Metabolism (1996)45(SuppM):21-23.
22. Rossowski WJ, Coy DH.Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem Biophys Res Commun (1994)205:341-346.
23. Raynor K, Murphy WA, Coy DH, Taylor JE. Moreau JP, Yasuda K, Bell Gl, Reisine T.Cloned somatostatin receptors.Identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol (1993) 43:838-844.
24. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, PetcherTJ, Pless J.SMS 201-995.A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sei (1982) 31:1133-1140.
25. Bass RT. Buckwalter BL, Patel BP, Pausen MH, Price LA, Stmad J, Hadcock JR.Identification and characterization of novel somatostatin antagonists. Mol Pharmacol (1996) 50:709-715.
26. Wilkinson GF, Thurtow RJ, Sellers, LA, Coote JE, Feniuk W, Humphrey PP.Potent antagonism by BIM-23056 at the human recombinant somatostatin ssts receptor. Br J Pharmacol (1996) 118:445-447.
27. Hocart SJ, Jain R, Murphy WA, Taylor JE, Morgan B, Coy DH.Potent antagonists of somatostatin.synthesis and biology. J Med Chem (1998) 41:1146-1154.
28. Baumbach WR, Carrick TA, Pausen MH, Bingham B, Carmignac D, Robinson 1C, Houghten R, Eppler CM, Price LA, Zysk JR.A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats. Mol Pharmacol (1998) 54:864-873.
29. • Design and biological activity of a peptidal antagonist of the SSTFI2.
30. Fitzpatrick VD, Vandlen RL.6 agonist selectivity determinants in somatostatin receptor subtypes I and II. J Biol Chem (1994) 269:24621-24626.
31. Liapakis G, Fitzpatrick D, Hoeger C, Rivier J, Vandlen R, Reisine T.Identification of ligand binding determinants in the somatostatin receptor subtypes 1 and 2. J Biol Chem (1996)271:20331-20339.
32. Kaupmann K, Bruns C, Raulf F, Weber H, Mattes H, Lubbert H.Two amino acids located in transmembrane domains VI and VII determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor. EMBO J (1995) 14:727-735.
33. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T. Butler B, Chan WW, Chaung LY, Judith F, Taylor J, Wyvratt MJ, Fisher MH.A nonpeptidyl growth hormone secretagogue. Sc/ence(1993) 260:1640-1643.
34. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, Jacks T, Schleim K, Pong SS, Chaung LY, Chen HY, Frazier E, Leung KH, Chiu SH, Smith RG.Design - and biological activities of L-163,191 (MK-0677).A potent orally active growth hormone secretagogue. P roc Natl Acad Sei USA (1995)92:7001-7005.
35. Swain CJ, Seward EM, Cascieri MA, Fong TM, Herbert R, Maclntyre DE, Merchant KJ, Owen SN, Owens AP, Sabin V, Teall M, VanNeil MB, Williams BJ, Sadowski S, Strader C, Ball R, Baker R.Identification of a series of 3-(benzyloxy)-1azabicyclo[2.2.2]octane human NK1 antagonists. J Med Chem (1995) 38:4793-4805.
36. Hale JJ, Mills SG, MacCoss M. Shah SK, Qi H, Mathre DJ. Cascieri MA, Sadowski S, Strader CD, Maclntyre DE, Metzger JM.2(S)-((3,5-bis(triftuoromethyl)benzyl)-oxy)-3(S)-phenyl4-((3-oxo-1,2,4- triazol-5-yl)methyl)morpholme (1).A potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. J Med Chem (1996) 39:1760-1762.
37. Yang L, Berk SC, Rohrer SP, Mosley RT, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Poor F, Pasternak A, Pan R, Suva M, Freidinger RM, Smith RG, Chapman K, Schaeffer JM, Patched AA.Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sei USA (1998) 95:10836-10841.
38. •• Demonstration of in vivo activity of a non-peptidal SSTR2 selective agonist.
39. Mosley RT, Miller MD, Kearsley SK, Prendergast K, Underwood DJ.New lead discovery in drug development. In.Computational Medicine, Public Health and Biotechnology (Part 1), Willen M (Ed). World Scientific Publishing, Singapore (1995):101-125.
40. • Molecular modeling methods used by the Merck group.
41. Kearsley SK, Underwood DJ, Sheridan RP, Miller MD.Flexibases.A way to enhance the use of molecular docking methods. J Comput Aided Mol Des (1994) 8:565582.
42. Berk SC, Rohrer S, Degrado S, Birzin E, Mosley R, Hutchins S, Pasternak A, Schaeffer J, Underwood, Chapman KT.A combinatorial approach towards the discovery of nonpeptide, subtype-selective somatostatin receptor ligands. J Combinatorial Chem (1999) in press.
43. •• Description of the chemical synthesis and activity of the first somatostatin receptor directed combinatorial library.
44. Yang L, Guo L, Pasternak A, Mosley R, Rohrer S, Birzin E, Poor F, Cheng K, Schaeffer J, Patchett AA.Spiro[1H-Indene1,4'-piperidine] derivatives as potent and selective nonpeptide human somatostatin receptor subtype 2 (sst2) agonists. JMedChem (1998) 41:2175-2179.
45. Pasternak A, Pan Y, Marino D, Sanderson PE, Mosley R, Rohrer SP, Birzin E, Huskey SEW, Jacks T, Schleim KD, Cheng K, Schaeffer JM, Patchett AA, Yang L.Potent, orally bioavailable somatostatin agonists.good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett (1999) 9:491-496.
46. • Synthesis of non-peptidal somatostatin analogs with good oral bioavailability.
47. Rohrer SP, Birzin ET. Mosley R, Berk SC, Hutchins S, Shen DM, Xiong Y, Hayes E, Parmar R, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM.Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (1998) 282:737-740.
48. •• The original manuscript describing the development of a panel of somatostatin receptor selective analogs.
49. Hirschmann R, Nicolaou KC, Pietranico S, Leahy EM, Salvino J, Arisen B, Cichy MA, Spoors PG, Shakespeare WC, Sprengeler PA, Hamley P, Smith AB III, Reisine T, Raynor K, Maechler L, Donaldson C, Vale W, Freidinger RM, Cascieri MR, Strader CD.De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing -O-glucose as a novel scaffolding. J Am Chem Soc (1993) 115:12550-12568.
50. Hirschmann R, Hynes J Jr, Cichy-Knight MA, van Rijn RD, Sprengeler PA, Spoors PG, Shakespeare WC, Pietranico-Cole S, Barbosa J, Yao W, Rohrer S, Smith AB.Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis. JMedChem (1998) 41:1382-1391.
51. • Alternative approach to synthesis of non-peptidal somatostatin receptor analogs.
52. Papageorgiou C, Borer X.A non-peptide ligand for the somatostatin receptor having a benzodiazepinone structure. Bioorg Med Chem Lett (1996) 6:267-272.
53. Ankersen M, Crider M, Liu S, Ho B, Andersen HS, Stidsen C.Discovery of a novel non-peptide somatostatin agonist with sst4 selectivity. JAm Chem Soc (1998) 120:1368-1373.
54. Liu S, Tang C, Ho B, Ankersen M, Stidsen CE, Crider AM.Nonpeptide somatostatin agonists with sst4 selectivity.synthesis and structure-activity relationships of thioureas. J Med Chem (1998) 41 =4693-4705.
55. Yang L.Non-peptide somatostatin receptor ligands. Ann Rep Med Chem (1999) in press.
56. • Comprehensive review of all somatostatin analogs discovered to date.